middle.news
Anteris Launches Global Trial After FDA Nod for DurAVR Heart Valve
9:16am on Monday 3rd of November, 2025 AEDT
•
Healthcare
Read Story
Anteris Launches Global Trial After FDA Nod for DurAVR Heart Valve
9:16am on Monday 3rd of November, 2025 AEDT
Key Points
FDA approval granted to start PARADIGM global pivotal trial
Trial to enroll ~1000 patients across US, Europe, and Canada
DurAVR THV compared head-to-head with commercial TAVR devices
Primary endpoint includes mortality, stroke, and cardiovascular hospitalization
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Anteris Technologies Global (ASX:AVR)
OPEN ARTICLE